Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

NB-1011 enters phase I/II trial in colon cancer

Jan. 8, 2002

Abgenix initiates phase II trial of ABX-EGF in prostate cancer

Jan. 8, 2002

CDK inhibitors useful as anticancer agents reported by LG Chem

Jan. 7, 2002

Shire and HydroMed realign histrelin agreement

Jan. 7, 2002

Kyowa Hakko and Lilly report new potent antitumor compounds

Jan. 4, 2002

New dosage form of Atrix's Leuprogel licensed in by Sanofi-Synthelabo

Jan. 4, 2002

Japanese researchers identify new steroid sulfatase inhibitors

Jan. 2, 2002

Sterol derivatives claimed as antiproliferative and antiangiogenic agents

Jan. 2, 2002

ImClone's BLA filing for Erbitux not accepted by FDA

Jan. 2, 2002

ABX-EGF enters phase II trial for colorectal cancer

Jan. 2, 2002

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 11, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...